サイト内検索

登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録

連絡先

TEL．03-5812-5270
FAX．03-3831-0495
E-mail：info@spi-information.com

関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。

Innovative Drug R&D in China

中国における革新的薬剤のR&D

レポート概要

中国の製薬業界は急成長し、より多くの中国の製薬企業が革新的薬剤の研究における投資に注目しています。彼らの試みは、経済的支援や産業構造を改善することを約束した政府が後押し、また、多数のベンチャーキャピタルによって進歩しています。

本レポートは、研究範囲や規模、革新的薬剤のR&Dにおける現在の焦点や能力、および製品パイプラインの開発状況など、中国における革新的薬剤のR&Dの実態を明らかにしました。

広範かつ詳細な調査に基づいて、中国における革新的薬剤のR&Dの現況を理解する手掛かりになります。また、中国のこの業界の潜在的な将来成長などを詳細に分析しました。

本レポートは、中国企業と共同研究を求めている世界の製薬およびバイテク企業、中国の製薬およびバイテク業界における投資機会に関心を持つベンチャー投資企業、中国の薬剤開発状況についての情報を求める調査会社、中国のバイテク業界の現在および将来の動向に関心を持つ政府機関にとっての必読書であります。

さらに、本レポートには、以下の12のケーススタディが紹介されています。

  • ケーススタディ1 新しいドラッグデリバリーを重点的に取り組む中国のバイテク企業
  • ケーススタディ2 国際的製薬企業による中国での特許申請の例
  • ケーススタディ3 既存治療薬の新剤形に対する中国企業の特許申請の例
  • ケーススタディ4 GSKが中国のワクチン市場を調査する
  • ケーススタディ5 北京市政によるR&Dの財政支援の発表
  • ケーススタディ6 新しいR&Dに財政支援する上海市政の発表
  • ケーススタディ7 中国漢方から抽出された天然物における主要欧米企業の関心
  • ケーススタディ8 革新的薬剤のR&Dにおける中国製薬企業と研究機関との協調
  • ケーススタディ9 中国の製薬企業とアメリカのバイテク企業間のR&Dの協調
  • ケーススタディ10 新規抗TB薬の開発における中国研究機関とアメリカを拠点とするNPOの協調
  • ケーススタディ11 欧米諸国にR&Dセンターを確立させた中国の製薬企業
  • ケーススタディ12 早期膀胱がんの発見のための診断ツールを開発する中国企業

レポート詳細

目次

Scope of the Report
About Author
Executive Summary
Current state of innovative drug R&D in China
Chinese companies conducting innovative drug R&D
Innovative drugs in development pipelines of Chinese drug companies
Future prospect of innovative drug R&D in China
Chapter 1. Current State of Innovative Drug R&D in China
Summary
1.1 Introduction
1.2 Innovative drug R&D in China: Possible?!
1.2.1 The lost history of innovative drug R&D in China
1.2.2 R&D activities on innovative medicines do exist in China now
1.2.3 Examples of Western pharma companies licensing drug candidates from China
1.3 Current state of innovative drug R&D in China's pharma-related industries
1.3.1 Innovative drug R&D in Chinese pharma and biotech industries
1.3.2 Innovative drug R&D in state-owned research institutions
1.4 Current state of R&D on traditional Chinese medicines (TCM)
1.5 Current capability of China's innovative drug R&D
1.5.1 China's general capability in pharmaceutical research
1.5.2 Capability of Chinese companies in innovative drug R&D
1.5.3 Capability of Chinese companies in development of new drug delivery technologies
1.5.4 Key strengths of Chinese drug companies in innovative drug R&D
1.5.5 Current situation of patent applications in China for innovative drugs
1.6 Current funding sources for innovative drug R&D in China
1.6.1 Initial public offering (IPO)
1.6.2 Self-funded
1.6.3 Venture capitals
1.6.4 Government grants
1.7 Importance of China's innovative drug R&D to the world pharma industry
1.7.1 Western pharma companies desperately need novel drugs to fill out their product pipelines
1.7.2 Novel drug candidates discovered and developed by Chinese companies could become alternative resources to Western companies
1.7.3 Financial crisis has enhanced the importance of China's innovative drug R&D to Western companies
Chapter 2. Chinese Companies Conducting Innovative Drug R&D
Summary
2.1 Introduction
2.2 Searching and selection criteria
2.3 Analysis of Chinese companies conducting innovative drug R&D
2.3.1 Business nature of the companies conducting innovative drug R&D in China
2.3.2 Experience of Chinese companies in innovative drug R&D
2.3.3 Analysis of financial support of all China-based innovative drug R&D companies
2.3.4 Analysis of physical locations of innovative drug R&D companies in China
2.4 Analysis of product pipelines of all Chinese companies conducting innovative drug R&D
2.4.1 Listing of product pipelines of Chinese drug companies
2.4.2 Analysis of product pipelines of Chinese drug companies
1. Distributions of drug candidates in various development stages in each group of companies
2. Distributions of innovative drug R&D companies focusing on small molecule drugs and macro compound-based drugs
3. Which companies own the most drug candidates
4. Analysis of innovative drug R&D companies according to therapeutic areas
Chapter 3. Innovative Drugs in Development Pipelines of Chinese Drug Companies
Summary
3.1 Introduction
3.2 Analysis of development stages of drug candidates in the product pipelines of Chinese drug companies
3.2.1 Distributions of development stages of all drug candidates
3.2.2 Detailed listing of all drug candidates in each development stage
3.3 Analysis of molecular structures of all drug candidates in development pipelines
3.3.1 Distributions of all drug candidates of different types of molecular structure
3.3.2 Detailed listing of drug candidates according to their molecular structure
3.4 Analysis of drug candidates in each therapeutic area
3.4.1 Analysis of drug candidates according to their therapeutic functions
3.4.2 Analysis of drug candidates in each therapeutic area according to their development stages
3.4.3 Detailed listing of drug candidates in each therapeutic area
Chapter 4. Future Prospect of Innovative Drug R&D in China
Summary
4.1 Introduction
4.2 Drivers of future development of innovative drug R&D in China
4.2.1 Attraction of China as one of the world largest pharmaceutical markets
1. Future development potentials of Chinese pharmaceutical market
2. Future market growth potentials of some key therapeutic areas
a. Market growth potential of anticancer drugs in China
b. Market growth potential of various vaccines in China
3. Key future growth drivers of Chinese pharmaceutical market
a. On-going nationwide healthcare reform
b. Westernization of living style has changed disease patterns
c. Growing middle class population that are able to afford high-end medicines
d. Rapid urbanization makes more Chinese able to afford high-end medicines
4.2.2 Government encouragement and support for innovative drug R&D
4.2.3 Increasing sources and availabilities of R&D funding
1. Various funding sources from government agencies
2. Increasing opportunities of venture capital (VC) investment
4.2.4 Gradual establishment of exit channels for investment
4.2.5 Advantages of conducting innovative drug R&D in China
1. Rich natural products
2. A large, treatment-na?ve patient pool
3. Abundant animal species
4. Large, well-trained workforce
4.2.6 Entrance of multinational companies
4.2.7 Collaborations between local Chinese drug R&D companies/organizations and between Chinese companies and experienced international drug companies
4.2.8 Summary of the future growth drivers of innovative drug R&D in China and analysis of the roles each of them will play
4.3 Latest development in other frontier pharmaceutical research in China
4.3.1 Development of novel molecular diagnostic tools and biomarkers
4.3.2 Stem cell research
4.4 Existing issues in China's innovative drug R&D
4.5 The future perspective of China's innovative drug R&D
List of Tables
Table 1. Representative state-owned research institutes in life science
Table 2. Representative state key labs in life science
Table 3. Representative top research universities having life science schools/colleges
Table 4. Products under development in Chinese biotech companies using new drug delivery/formulation techniques
Table 5. List of representative companies/research organizations in China conducting innovative drug R&D
Table 6. Classifications and distributions of China-based innovative drug R&D companies
Table 7. Years of innovative drug R&D experience of Chinese companies
Table 8. Classifications of founders of Chinese companies conducting innovative drug R&D
Table 9. Innovative drug R&D companies founded by returnees or Chinese scholars
Table 10. Analysis of funding sources of China-based drug R&D companies
Table 11. Analysis of locations of China-based innovative drug R&D companies
Table 12. Major Chinese pharma companies conducting innovative drug R&D and their product pipelines
Table 13. Chinese biotech companies conducting innovative drug R&D and their product pipelines
Table 14. State-owned research institutes conducting innovative drug R&D and their product pipelines
Table 15. Chinese CROs conducting innovative drug R&D and their product pipelines
Table 16. Analysis of drug product pipelines in each group of innovative drug R&D companies
Table 17. Analysis of the numbers of the innovative drug R&D companies in each drug development stage
Table 18. Analysis of molecular structure of drug candidates in each group of Chinese companies conducting innovative drug R&D
Table 19. Top 10 companies having most innovative drug candidates
Table 20. Analysis and distributions of innovative drug R&D companies according to therapeutic areas
Table 21. China-based Innovative drug R&D companies having cancer drugs in various development stages
Table 22. China-based innovative drug R&D companies having anti-viral drugs in various development stages
Table 23. Analysis of the numbers of drug candidates in each development stage
Table 24. Drug candidates in preclinical development
Table 25. Drug candidates in phase I development
Table 26. Drug candidates in phase II (IIa/IIb) development
Table 27. Drug candidates in phase III development
Table 28. Drugs approved or waiting for approval
Table 29. Classifications and distributions of drug candidates according to their molecular structures
Table 30. Distributions of small molecule drugs in various development stages
Table 31. Distributions of macro compound-based drugs in various development stages
Table 32. List of small molecule drugs in various development stages
Table 33. List of macro compound-based drugs in various development stages
Table 34. List of vaccines in development for different purposes
Table 35. List of new TCMs in development
Table 36. Distributions of drug candidates in each therapeutic area
Table 37. Summary of the mechanisms of action of all cancer drugs in development
Table 38. Numbers of drugs in various development stages of each therapeutic area
Table 39. Drug candidates in development for cancer
Table 40. Drug candidates in development for anti-viral diseases
Table 41. Drug candidates in development for cardiovascular diseases
Table 42. Anti-biotic drugs in development
Table 43. Drug candidates in development for metabolic diseases
Table 44. Drug candidates in development for inflammatory diseases
Table 45. Drug candidates in development for CNS diseases
Table 46. Drug candidates in development for COPD
Table 47. Drug candidates in development for all other diseases
Table 48. Current Chinese pharmaceutical market and its future growth forecasts
Table 49. Representative venture capital investors in China
Table 50. Examples of recent investment activities of Western VCs in China
Table 51. Analysis of the roles of growth drivers in determining the future development of China's innovative drug R&D
Table 52. Diagnostic products under development
Table 53. Stem cell research in China

List of Figures
Figure 1. Distributions of different types of innovative drug R&D companies in China
Figure 2. Distributions of innovative drug R&D companies in term of the years of their research experience
Figure 3. Graphic display of funding sources of China-based innovative drug R&D companies
Figure 4. Location distributions of innovative drug R&D companies in China
Figure 5. Distributions of the number of drug candidates and their development stages in each group of companies
Figure 6. Distributions of companies in each development stage of drug R&D
Figure 7. Comparison of the numbers between small molecule drugs and macro compound drugs in each group of innovative drug R&D companies
Figure 8. Company distributions in each therapeutic area
Figure 9. Distributions of development stages of all drug candidates
Figure 10. Comparison of the numbers between small molecule drugs and macro compound-based drugs in development pipelines
Figure 11. Distributions of small molecule drugs in various development stages
Figure 12. Distributions of macro compound-based drugs in various development stages
Figure 13. Numbers of drug candidates in each therapeutic area
Figure 14. Distributions of drug product pipelines in each therapeutic area
Figure 15. Development of Chinese pharmaceutical market: Past, present and future
Figure 16. Current market value and forecasted future growth of cancer drug market in China
Figure 17. Current market value and forecasted future growth of vaccine market in China
Figure 18. Major Western pharma and biotech companies conducting innovative drug R&D in China
List of Case Studies
Case study 1. Chinese biotech company focusing on development of new drug delivery technologies
Case study 2. Example of application for Chinese patent by international drug companies
Case study 3. Example of patent application by Chinese company for new formulation of existing drugs
Case study 4. GSK looking at the Chinese vaccine market
Case study 5. Latest announcement of more R&D funding by Beijing Municipal Government
Case study 6. Latest announcement by Shanghai Municipal Government for availability of new R&D funding
Case study 7. The interest of major Western pharma companies in natural products derived from medicinal herbs of TCMs
Case study 8. Collaboration between Chinese drug company and research institution on innovative drug R&D
Case study 9. R&D collaboration between a Chinese pharma company and a US biotech company
Case study 10. Chinese research institute collaborating with a US-based non-profit organization on development of novel anti-TB agents
Case study 11. Chinese pharma company establishing R&D centers in the Western countries
Case study 12. Chinese company developing diagnostic tools for detection of early stage bladder cancer
Company Profile
Company profiles of 40 Chinese companies conducting innovative drug R&D
Appendix
Appendix I. Research methodology
Appendix II. About JZMed

発刊日

2009/10/01

体裁

PDF / 230ページ

販売価格

2,895USD

発行

JZMed Inc

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

関連カテゴリ

創薬一般

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる

PAGE